Compare FDC LTD. with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FDC LTD. vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FDC LTD. AJANTA PHARMA FDC LTD./
AJANTA PHARMA
 
P/E (TTM) x 17.5 23.5 74.5% View Chart
P/BV x 2.4 4.1 57.2% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 FDC LTD.   AJANTA PHARMA
EQUITY SHARE DATA
    FDC LTD.
Mar-18
AJANTA PHARMA
Mar-19
FDC LTD./
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs3191,422 22.4%   
Low Rs164898 18.3%   
Sales per share (Unadj.) Rs61.6233.5 26.4%  
Earnings per share (Unadj.) Rs9.944.0 22.6%  
Cash flow per share (Unadj.) Rs12.052.2 22.9%  
Dividends per share (Unadj.) Rs09.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs73.2255.1 28.7%  
Shares outstanding (eoy) m174.4088.02 198.1%   
Bonus/Rights/Conversions BBBB-  
Price / Sales ratio x3.95.0 78.9%   
Avg P/E ratio x24.326.4 92.0%  
P/CF ratio (eoy) x20.222.2 90.8%  
Price / Book Value ratio x3.34.5 72.6%  
Dividend payout %020.5 0.0%   
Avg Mkt Cap Rs m42,118102,081 41.3%   
No. of employees `0005.56.8 81.3%   
Total wages/salary Rs m2,1674,307 50.3%   
Avg. sales/employee Rs Th1,943.73,022.6 64.3%   
Avg. wages/employee Rs Th391.7633.4 61.8%   
Avg. net profit/employee Rs Th313.7569.1 55.1%   
INCOME DATA
Net Sales Rs m10,75120,554 52.3%  
Other income Rs m510211 241.7%   
Total revenues Rs m11,26020,765 54.2%   
Gross profit Rs m2,2675,664 40.0%  
Depreciation Rs m351721 48.8%   
Interest Rs m1412 120.7%   
Profit before tax Rs m2,4115,143 46.9%   
Minority Interest Rs m-50-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6711,273 52.7%   
Profit after tax Rs m1,7353,870 44.8%  
Gross profit margin %21.127.6 76.5%  
Effective tax rate %27.824.8 112.5%   
Net profit margin %16.118.8 85.7%  
BALANCE SHEET DATA
Current assets Rs m7,21311,812 61.1%   
Current liabilities Rs m2,1043,776 55.7%   
Net working cap to sales %47.539.1 121.5%  
Current ratio x3.43.1 109.6%  
Inventory Days Days5477 70.4%  
Debtors Days Days2882 34.0%  
Net fixed assets Rs m6,86514,398 47.7%   
Share capital Rs m175175 99.9%   
"Free" reserves Rs m12,58622,277 56.5%   
Net worth Rs m12,76122,452 56.8%   
Long term debt Rs m67 90.9%   
Total assets Rs m15,04126,962 55.8%  
Interest coverage x173.2444.3 39.0%   
Debt to equity ratio x00 159.9%  
Sales to assets ratio x0.70.8 93.8%   
Return on assets %11.614.4 80.8%  
Return on equity %13.617.2 78.9%  
Return on capital %19.023.0 82.6%  
Exports to sales %12.30-   
Imports to sales %00-   
Exports (fob) Rs m1,327NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,88910,682 17.7%   
Fx outflow Rs m02,102 0.0%   
Net fx Rs m1,8898,580 22.0%   
CASH FLOW
From Operations Rs m1,4983,748 40.0%  
From Investments Rs m201-2,228 -9.0%  
From Financial Activity Rs m-1,694-1,475 114.9%  
Net Cashflow Rs m1045 22.8%  

Share Holding

Indian Promoters % 68.9 73.8 93.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.7 1.6 303.2%  
FIIs % 7.5 7.6 98.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.0 17.0 111.8%  
Shareholders   23,730 20,968 113.2%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FDC LTD. With:   DISHMAN PHARMA  CADILA HEALTHCARE  AUROBINDO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  

Compare FDC LTD. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

FDC LTD. Announces Quarterly Results (1QFY20); Net Profit Up 2.4% (Quarterly Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

For the quarter ended June 2019, FDC LTD. has posted a net profit of Rs 523 m (up 2.4% YoY). Sales on the other hand came in at Rs 3 bn (up 17.9% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

FDC LTD. Announces Quarterly Results (4QFY19); Net Profit Up 6.8% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, FDC LTD. has posted a net profit of Rs 337 m (up 6.8% YoY). Sales on the other hand came in at Rs 3 bn (down 0.6% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FDC LTD. SHARE PRICE


Sep 20, 2019 (Close)

TRACK FDC LTD.

  • Track your investment in FDC LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FDC LTD. - STRIDES PHARMA SCIENCE COMPARISON

COMPARE FDC LTD. WITH

MARKET STATS